PharmaNet Development Group, Inc., a provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Carl Spalding has joined the Company's Board of Directors.
"We are very pleased to have Carl join our Board," commented Jeffrey P. McMullen, President and Chief Executive Officer. "His depth of experience with clinical development, from the perspective of both a contract research organization and pharmaceutical company, will be a valuable asset to the shared vision and guidance of our Board of Directors." Mr. Spalding is past President and Chief Operating Officer of PAREXEL, a publicly-traded, global contract research organization. Prior to joining PAREXEL, Mr. Spalding held senior positions at major healthcare companies, including Cardinal Health, Abbott, and Johnson & Johnson.